Daniela Dolciami

Daniela Dolciami

Auto-generated profile, based on publicly available information

Daniela Dolciami

Department of Pharmaceutical Sciences, University of Perugia, via del Liceo, 1 - 06123, Perugia, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2014 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
RNRoberto Nuti
Roberto Nuti
Marco GargaroMarco Gargaro
Marco Gargaro
DMDavide Matino
Davide Matino
DDDaniela Dolciami
Daniela Dolciami
UGUrsula Grohmann
Ursula Grohmann
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo

16 May 2017 in MedChemComm
Verified
Journal Article
Open access
PDF file
ACAlice Coletti
Alice Coletti
FGFrancesco Antonio Greco
Francesco Antonio Greco
DDDaniela Dolciami
Daniela Dolciami
ECEmidio Camaioni
Emidio Camaioni
RSRoccaldo Sardella
Roccaldo Sardella
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo
Structure–function relationships of IDO1 and structure–activity relationships of inhibitors are discussed with an outlook on next generation IDO1 ligand.

23 January 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
DDDaniela Dolciami
Daniela Dolciami
Marco GargaroMarco Gargaro
Marco Gargaro
Bruno CerraBruno Cerra
Bruno Cerra
GSgiulia scalisi
giulia scalisi
LBLuana Bagnoli
Luana Bagnoli
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo

19 July 2016 in Molecular Informatics
Verified
Journal Article
Open access
PDF file
FGFrancesco Antonio Greco
Francesco Antonio Greco
ABAnswald Bournique
Answald Bournique
ACAlice Coletti
Alice Coletti
CCChiara Custodi
Chiara Custodi
DDDaniela Dolciami
Daniela Dolciami
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo
In the last decade, indoleamine 2,3‐dioxygenase 1 (IDO1) has attracted a great deal of attention being recognized as key regulator of immunosuppressive pathways in the tumor immuno‐editing process. Several classes of inhibitors have been developed as potential anticancer agents, but only few of them have advanced in clinical trials. Hence, the quest of novel potent and selective inhibitors of the enzyme is still active and mostly pursued by structure‐based drug design strategies based on early and more recent crystal structures of IDO1. Combining docking studies and molecular dynamic simulations, in this work we have comparatively investigated the structural features of each crystal structure of IDO1. The results pinpoint different features in specific crystal structures of the enzyme that may benefit the medicinal chemistry arena aiding the design of novel potent and selective inhibitors of IDO1.

3 August 2017 in Future Medicinal Chemistry
Verified
Journal Article
Open access
FGFrancesco Antonio Greco
Francesco Antonio Greco
ACAlice Coletti
Alice Coletti
CCChiara Custodi
Chiara Custodi
DDDaniela Dolciami
Daniela Dolciami
Alessandro Di MicheleAlessandro Di Michele
Alessandro Di Michele
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo
Inhibition of IDO1 is a strategy pursued in the immune-oncology pipeline for the development of novel anticancer therapies. At odds with an ever-increasing number of inhibitors being disclosed in the literature and patent applications, only very few compounds have hitherto advanced in clinical settings. We have used MicroScale Thermophoresis analysis and docking calculations to assess on a quantitative basis the binding properties of distinct categories of inhibitors to IDO1. Results shed further light on hidden molecular aspects governing the recognition by the enzyme of compounds with different mechanism of inhibition. Results pinpoint specific binding features of distinct inhibitors to IDO1 that offer clues for the design of next-generation inhibitors of the enzyme.

1 September 2018 in Natural Product Communications
Verified
Journal Article
Open access
PDF file
SFSerena Fiorito
Serena Fiorito
FGFrancesco A. Greco
Francesco A. Greco
ACAlice Coletti
Alice Coletti
DDDaniela Dolciami
Daniela Dolciami
SVSilvia Viola
Silvia Viola
AMAntonio Macchiarulo
Antonio Macchiarulo
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key target for the development of small molecule immunotherapies in oncology. In this framework, the screening of chemotherapeutic agents to identify compounds binding to IDO1 represents a valuable strategy for the development of multitarget drug candidates that combine synergic immunoregulatory properties to cytotoxic activity. In this study, we report that two natural compounds endowed with anticancer activity, namely lapachol and auraptene, act as IDO1 ligands with dissociation constant (Kd) in the micromolar range of potency. Docking studies provide plausible binding modes of these compounds to the catalytic cleft of IDO1. Our results support the notion that lapachol and auraptene may be considered interesting lead compounds in the immuno-oncology setting.